Purpose. Pasteurella multocida (P. multocida) is a principal pathogen of domestic animals and an opportunistic pathogen of humans. It is the causative agent of pneumonia and haemorrhagic septicaemia in cattle, sheep and goats, fowl cholera in chickens and progressive atrophic rhinitis in swine. In this study, we investigated the humoral and cellular immune responses and protective immunity conferred by an iron-inactivated vaccine with bacterial DNA (IIV+bDNA) as an adjuvant in mice.
INTRODUCTION
Among Gram-negative bacterial pathogens, Pasteurella multocida (P. multocida) is known to be associated with diverse infectious diseases of livestock worldwide and possesses several virulence factors [1] .
P. multocida strains are classified into serogroups (A, B, D, E and F) based on differences in the capsular polysaccharide antigens, and are further classified into 16 serotypes (1-16) based primarily on lipopolysaccharide antigens [2, 3] . This pathogen is considered an aetiological agent of numerous economically important diseases, including pneumonia and haemorrhagic septicaemia in cattle, sheep and goats, fowl cholera in chicken and progressive atrophic rhinitis in swine [2, 4] . Traditional vaccines (killed or inactivated) have played vital roles in controlling and eradicating infectious diseases for a long time [4] .
Because of the relatively low incidence of human infection, most immunization or vaccination studies on Pasteurella infection have been geared toward controlling animal disease [5] . Despite considerable effort and ample experimental animal models, mechanisms of protective immunity against Pasteurella remain elusive and so the development and evaluation of effective vaccines have been challenging [5] .
One of the most widely used vaccines in Asia is the wholecell formalin killed P. multocida P52 bacterin emulsified in aluminum hydroxide gel (generically known as alum). This vaccine, however, does not provide long-lasting immunity. It is therefore obvious that difficulties are being encountered in the production of vaccines for P. multocida, which may be due to its high antigenic variability and the low level of work reported on whole-genome sequencing [6] .
For decades, alum has been used successfully in vaccine preparations and has a good safety record. However, alum is a weak adjuvant for antibody induction against protein subunits and is a poor adjuvant for cell-mediated immunity. In addition, alum can cause severe local reactions such as erythema, subcutaneous nodules and contact hypersensitivity [7] . Therefore, there is a need for the development of new adjuvant strategies. Ideal adjuvants should be cheap, biodegradable, biologically inert and boost the cellular and humoral immune responses in addition to having a long shelf-life [8] .
An adjuvant that induces T helper 1 (Th1) cells or balanced immune responses would, therefore, be a candidate component of a successful vaccine formulation [9] . Bacterial DNA (b-DNA) containing CpG motifs is one of the most potent cellular adjuvants. Bacterial DNA can incite macrophages, monocytes and dendritic cells in a CpG-dependent manner that then produce multiple various cytokines, including the Th1 cytokine interleukin 12. This effect synergizes with CpG oligodeoxynucleotides (ODN) to stimulate NK cell production of interferon gamma [10, 11] . CpG ODN is composed of short pieces of DNA containing unmethylated CG dinucleotides that generally induce an overall Th1-type immune response [9] .
Mapletoft et al. have previously shown the adjuvant effects of CpG ODN on parenteral formalin-inactivated bovine respiratory syncytial virus vaccines in mice and calves [9] .
At high concentrations, heavy metal ions react to form toxic compounds in bacterial cells. The use of iron as an inactivated agent rather than formalin was reported by Kumar and Singh [12] and Herath et al. [13] . Kumar and Singh inactivated S. typhimurium with a high concentration of FeCl 3 (>10 mM) that resulted in the generation of toxic free radicals to degrade bacterial DNA and kill bacteria intended for use in inactivated vaccines [12] . Herath et al. inactivated P. multocida using a high dose of FeCl 3 (100 mM) to protect chickens from fowl cholera [13] . The purpose of the present study was to verify the humoral and cellular immune responses in Balb/c mice inoculated with the ironinactivated vaccine adjuvanted with bDNA, and to show that this preparation is superior to the formalin-inactivated P. multocida vaccine.
METHODS Animals
The female Balb/c mice (weight 16-18 g) used in this work were provided by the Animal House of the Razi Vaccine and Serum Research Institute (RVSRI), Shiraz, Iran. The animals were kept in micro-isolators and all experiments were conducted in accordance with the guidelines for the care and use of experimental animals of the National Council of Animal Experimentation Control. The mice had not previously been vaccinated against pasteurellosis. They were used in the study of vaccine efficacy, humoral and cellular immune responses and vaccine safety studies.
P. multocida isolation and culture P. multocida A strain PMSHI-9 (Genbank accession number: JF694004.1) sheep isolate used in the study was obtained from the Division of Bacteriology, RVSRI, Shiraz, Iran. For isolation of single colonies, bacteria were cultured on blood agar base (Merck Company) containing 5 % defibrinated sheep blood, and were incubated for 24 h at 37 C. For broth cultures, P. multocida was inoculated into brainheart infusion (BHI) broth (Merck) and incubated in a shaking incubator (IKA, KS4000i; 100 rpm) overnight at 37 C. The purity of the culture was tested by Gram's staining.
For LD 50 estimation, P. multocida was grown in BHI broth, intraperitoneally (i/p) inoculated into Balb/c mice and the density was adjusted to contain 1.5Â10 7 bacterial cells ml À1 [14] . The suspension was used for ip inoculation of mice in the challenge test.
Effect of iron on P. multocida viability The overnight culture of P. multocida was inoculated in BHI broth supplemented with 1, 2.5, 5, 7.5, 10, 25, 50 and 75 mM ferric chloride, the incubation being performed at 37 C for 1, 4, 12 and 24 h. Total and viable bacterial counts were performed in McFarland's (Brown) opacity tubes and the spread plate method, respectively. For Brown opacity tubes, the bacterial suspension was transferred to the opacity tube to give a column 5-7 cm high. The tube was placed against a clearly printed page in good light and the opacity tubes were compared indvidually to the sample tube; the tube that most closely matched the suspension was selected. In spread plate method, the sample was suitably diluted and a little aliquot transferred on the agar plate surface. The bacteria were then equally distributed over the surface by a special streaking technique. After colonies were grown, the total number of bacteria were counted. The data obtained was used for determining the inactivating concentration of FeCl 3 [12] .
Isolation and purification of P. multocida bDNA Bacterial DNA was isolated using the method outlined by Cheng and Jiang [15] . This DNA extraction method is an improvement on the standard phenol/chloroform method. These authors eliminated the lysis step that uses SDS/lysozyme or proteinase K, and lysed the cells directly by phenol.
RNA in the DNA preparation was digested by RNase treatment and DNA was further purified by repeated chloroform treatments. Finally, the purified DNA was precipitated by two volumes of cold ethanol, pelleted, air-dried, re-suspended in endotoxin-free water and stored at À20 C until further use. The purity and yield of the DNA were assessed spectrophotometrically by calculating the A 260 /A 280 ratios and the A 260 values to determine protein impurities and DNA concentrations.
Preparation of formalin-inactivated vaccine (FIV)
For formalin inactivation, a typical isolated P. multocida colony on BA plates was selected and inoculated into 5 ml of BHI broth and incubated at 37 C for 24 h, then 1 ml of the bacterial culture obtained was further inoculated into 50 ml of BHI broth at 37 C for 24 h. Finally, bacterial growth was extended by inoculating 20 ml into 1 l of BHI broth at 37 C for a maximum of 24 h as a static culture [13] .
Bacteria were pelleted at 3500 r.p.m. for 30 min at 4 C and washed twice with a pyrogen-free normal saline solution (NSS). The pellet was resuspended in NSS to a final volume of 20 ml. Formaldehyde (37 %) (equivalent to formalin 100 %) was added to a final concentration of 0.5 % formalin in the suspension, mixed well and incubated at 37 C for 24 h. The residual formaldehyde was removed by washing the bacteria twice in NSS. Finally, the bacterial suspension was made up to 20 ml in NSS and stored at 4-8 C in a refrigerator [12, 13] . This preparation was designated as the formalin-inactivated vaccine (FIV). FIV was adjuvanted with 0.5 % aluminum potassium sulfate, and this experimental vaccine was designated as FIV+Alum. For the preparation of FIV+bDNA, FIV was adjuvanted with P. multocida A genomic DNA (bDNA).
Preparation of iron-inactivated vaccine (IIV)
Bacterial growth and harvesting of P. multocida were carried out as mentioned in the previous section. Iron inactivation of the bacteria was achieved by adding 1M FeCl 3 to the bacterial culture up to a final concentration of 10 mM. This bacterial suspension, containing 10 mM FeCl 3 , was then incubated at 37 C for 4 h with intermittent shaking. The bacteria were then pelleted by centrifugation and washed twice in NSS to remove excess FeCl 3 . Finally, the FeCl 3 -treated bacterial suspension was made up to 20 ml in NSS and stored at 4-8 C in a refrigerator [12, 13] . This preparation was designated as the iron-inactivated vaccine (IIV). IIV was adjuvanted with bDNA and this experimental vaccine was designated as IIV+bDNA. For the preparation of IIV+Alum, IIV was adjuvanted with 0.5 % aluminum potassium sulfate. Iron content used in the preparation of IIV was determined as described above (Effect of iron on P. multocida viability).
Vaccine sterility
To detect residual live organisms and contaminants, 200 µl suspensions of bDNA, FIV and IIV suspensions were inoculated onto NA and BA plates and in BHI broth at 37 C. The inoculated media were observed daily for 7 days for any signs of bacterial growth.
Safety/innocuity of experimental vaccines
Vaccine safety was assessed by observation of the general behavior of the mice, and of local and generalized reactions one week after vaccination. The mice were also observed for any signs of discomfort, anorexia, psychological disturbances and effects on body temperature and weight during the entire period of experimentation.
Immunization of mice with experimental vaccine Seventy Balb/c mice (age 4-5 weeks) were randomly distributed in seven groups each consisting of 10 mice. The animals were inoculated twice (primary and booster) by the s/c route at an interval of two weeks, using a dose of 1 mg/ 0.2 ml per mouse. The amount of pure bDNA alone or as an adjuvant in IIV and FIV was 5 µg, mixed in the 0.2 ml final volume of each inoculum. FIV vaccine was adjuvanted with 0.5 % alum (FIV+Alum) and 5 µg of bDNA (FIV+bDNA) and FIV without adjuvant. IIV was adjuvanted with 0.5 % alum (IIV+Alum), 5 µg of bDNA (IIV+bDNA) and IIV without adjuvant. Mice in the three parallel control groups received either NSS, Alum or bDNA adjuvant only, while the NSS control group received 0.2 ml NSS per mouse [13] .
Pre-immune sera were collected from blood samples of all mice in the seven groups and designated as 'd0' (day 0) sera. After primary immunization, 'd7' and 'd14' sera samples of each mouse were obtained and stored at À20 C until use. After 'd14' sera collection, the mice were immunized a second time (booster immunization) and sequential weekly sera samples (i.e. 'd21', 'd28', 'd35', 'd42' and 'd49') were collected from each mouse and stored at À20 C. Weekly sera samples in each group were obtained for determination of antibody titres by enzyme-linked immunosorbent assay (ELISA). Thus d0, d7, d14, d21, d28, d35, d42 and d49 sera samples in seven different groups were available for ELISA testing [12] .
Evaluation of humoral immune response in immunized mice
The humoral immune response was determined to measure the immunoglobulin G (IgG) antibody titres via indirect ELISA using sera collected from vaccinated mice. A chequerboard analysis was performed to identify the optimal antigen concentration and dilutions of the sera and the antibody conjugate. Polystyrene immunoplates (SPL, Korea) were coated with 200 ng of P. multocida antigen per well, diluted in carbonate-bicarbonate buffer pH 9.6 and incubated overnight at 4 C. The plates were washed once with PBS-0.05% Tween 20 (PBS-T) and were blocked with 100 µl of 1 % bovine serum albumin (BSA) at 37 C for 1 h. After washing three times with PBS-T, serum (diluted 1 : 50) was added and the plates were incubated for 1 h at 37 C. The plates were washed three times with PBS-T, rabbit antimouse IgG horseradish peroxidase (HRPO) conjugated (DakoCytomation, Denmark), diluted to 1 : 3000 was added, and the plates were incubated at 37
C for 1 h. After washing five times with PBS-T, the reactions were developed using o-phenylenediamine dihydrochloride (Dako) and hydrogen peroxide (OPD/H 2 O 2 substrate solution). The reaction was stopped by adding 0.1M sulfuric acid and the absorbance (OD) was determined at 450 nm with a microplate reader (BioTek Instruments, USA). The mean values were calculated from serum samples, which were assayed in triplicate [7] .
Evaluation of cellular immune response in immunized mice
Spleen lymphocyte transformation testing On day 28 after the first immunization (14th day after booster immunization), the mice were sacrificed and their spleens were aseptically removed by sterile techniques and placed in a cell culture-grade, sterile disposable 60 mm Petri dish containing 5-10 ml of incomplete Roswell Park Memorial Institute (RPMI) medium (Sigma). The spleens were separated with mouse tooth tongs by gently rending the shell and releasing the cells. The spleen cells were transferred to sterile tubes, which were placed in an ice bath for 4-5 min to allow particles to settle, and the suspension of dissociated cells was transferred to a graduated taper tube, followed by centrifugation for 10 min at 4 C and 1000 r.p.m. Erythrocytes were removed by hypo-osmotic shock and the remaining cells were washed three times with RPMI medium. After centrifugation, the supernatant was removed and the pellet resuspended in 5-10 ml of complete medium (RPMI medium supplemented with 2 % heat-inactivated fetal calf serum, Gibco) per spleen. The spleen cell number was adjusted to 1Â10 6 cells ml À1 [16] .
Each spleen cell suspension was divided into two parts and added to two-well culture plates (1 ml per well). One hundred microlitres of P. multocida antigen was added to one well (test) while another acted as a control. Culture plates were incubated at 37 C in a humidified incubator containing 5 % CO 2 in air. After 48 h, the supernatants were harvested and stored at À20 C for cytokine assay.
IL-6 and IL-12 ELISA assay Spleen cell culture supernatants were assayed for the presence of IL-6 and IL-12 using Eastbiopharm mouse Interleukin 12 (IL-12/P40) and Interleukin 6 (IL-6) ELISA Kits according to the manufacturer's instructions. These kits use ELISA based on the double-antibody biotin sandwich technique to assay mouse interleukin 12 and interleukin 6. For IL-12 detection, briefly, interleukin 12 (IL-12/P40) was added to the wells, which were pre-coated with interleukin 12 (IL-12/P40) monoclonal antibody and then incubated. Next, anti IL-12/P40 antibodies tagged with biotin were added to combine with streptavidin-HRP, forming an immune complex. After incubation, unbound enzymes were removed and washed then substrates A and B were added. The solution turned blue then yellow due to the use of stop solution (acid). For evaluation, a blank well was taken as zero; the absorbance (OD) of each well was measured at 450 nm wavelength, which was then read within 10 min after addition of the stop solution. The colour of the solution and the concentration of mouse interleukin 12 (IL-12/ P40) are positively correlated. For IL-6 detection, the preocedure is identical except that different materials are supplied in the kit.
Challenge of immunized animals with virulent P. multocida On day 28 after the secondary immunization, the mice were challenged with i/p inocula of 200 µl of 24 h growth of live P. multocida at 10 À3 dilution (containing 1.5Â10 7 c.f.u. ml
À1
, equivalent to 1422ÂLD 50 ). The mice were monitored daily for two weeks post-challenge for morbidity and mortality, and the survival number and protection rate were counted.
Statistical analysis
All data were subjected to statistical analysis, including calculation of the mean and standard error. Differences between control and treated groups were tested for significance using a one-way analysis of variance (ANOVA) and Bonferroni post hoc test. Differences were considered significant at P values <0.05.
RESULTS LD 50 of P. multocida
The LD 50 was found to be 1.5Â10 7 c.f.u. ml
À1
, indicating that this strain of P. multocida was of moderate virulence in outbred Balb/c mice at 4-6 weeks of age when saline suspension containing P. multocida was inoculated by the i/p route.
Effect of iron on viability of P. multocida Total bacterial counts of P. multocida at 10, 25, 50 and 100 mM FeCl 3 did not increase significantly at 24 h following inoculation. The viability of P. multocida at 7.5 mM FeCl 3 in BHI broth was <5Â10 8 c.f.u. ml À1 at 24 h and was zero at 10 mM FeCl 3 in BHI broth when measured at 24 h. The viability of P. multocida at 25 mM FeCl 3 was zero even when measured after incubation for 4 h.
FIV and IIV and vaccine sterility P. multocida grown in BHI broth and suspended in NSS was inactivated completely by 0.5 % formalin and 10 mM FeCl 3 for 24 h at 37 C in the preparation of FIV and IIV, respectively.
FIV, IIV and bDNA all showed an absence of any bacterial contaminants when grown on various media including BA, NA and BHI broth. All vaccine preparations were completely devoid of live organisms.
Extraction and purification of chromosomal DNA Chromosomal DNA extracted was found to be free of RNA and proteins as measured by A 260 /A 280 ratio (=1.8). After phenol/chloroform extraction, the bDNA concentration was found to be 250 ng µl
, which was used as the vaccine adjuvant.
Safety of the vaccines in mice
Mice were injected s/c with FIV+Alum, FIV+bDNA, IIV+Alum and IIV+bDNA for safety studies. No generalized reactions were noticed in any group. There were no appreciable signs of local or generalized reactions in any animals. No abscess or granuloma formation was noted in any of the vaccinated mice. The general condition of the animals remained stable for the duration of the experiments except for one day after each inoculation. There was no observation of abnormal temperature rise in any of the tested groups.
Specific humoral immune responses
The presence of serum anti-P. multocida antibody was determined on different days post-immunization by indirect ELISA. Group I received an injection of FIV+Alum, group II with FIV+bDNA, group III with IIV+bDNA, group IV with IIV+Alum, group V with IIV, group VI with FIV, group VII with Alum, group VIII with bDNA and group IX with NSS. Fig. 1 shows that the immunoglobulin content was increased by different amounts in the sera of vaccinated mice. The levels of antibody were significantly higher in the sera from groups I and III than in those from group II from 14 days after vaccination (P=0.0203). The antibody levels of groups II and III were also statistically significantly higher than those of group I from 35 days post-vaccination (P=0.0063). These results were obtained using the Bonferroni test.
Antibody titres rose to high levels 7 days after booster immunization in all of the four vaccinated groups, i.e. I-IV. Antibody titres were higher than d14 titres in these groups even up to 28 days (d42) after booster immunization. Peak antibody titres of 0.362, 0.318, 0.372 and 0.348 in groups I, II, III and IV, respectively, were recorded at d28.
Interleukin levels in immunized mice
The results showed that, compared with those of controls, the content of IL-6 significantly increased in samples from mice treated with FIV+bDNA and IIV+bDNA enwrapped with FIV+Alum and IIV+Alum (P=0.0371) (Fig. 2) . Using the Bonferroni test we recorded the following results for the levels of IL-12. There were no significant differences among groups I, V, VI, VII and IX. Also, there were no significant differences between groups IV and VIII. H the levels of IL-12 in the IIV+bDNA group (III) were markedly higher than those in the FIV+Alum group (I) from 28 days post-immunization (P=0.0259). Peak IL-6 and IL-12 titres of 33.85 and 10.97 ng l À1 were recorded in groups II and III, respectively.
Challenge results
The efficacy of FIV+Alum, FIV+bDNA, IIV+bDNA, IIV+-Alum, IIV and FIV was studied using a lethal dose of P. multocida administered by the i/p route and observation for 2 weeks post-challenge. Using the log-rank test, extremely statistically significant differences between the protection levels of vaccinated groups and the NSS and DNA control groups were found (P=0.0002). In the negative control mice, no casualties or disease occurred before the challenge. However, 4 days after the challenge the first casualties occurred and by day 7, all mice in these groups had died. There were no casualties in groups IIV and FIV before the challenge, but from day 7, symptoms of disease were observed in three sets of mice in each group. Six mice died on day 14 and only two survived from each group. There were no specific symptoms of disease in the FIV+Alum, FIV +bDNA and IIV+Alum groups, but in one mouse in each group from the 12th day disease symptoms appeared and these remained alive until the 21st day, but eventually they died. Only in group III, which was immunized with IIV +bDNA, were 100 % of the mice still alive on the 28th day (Fig. 3) . Moreover, pathological examination showed that the organs and tissues of surviving mice were normal and there was no observation of body weight loss in these groups (Fig. 4) . Using the Bonferroni test we found no significant differences in body weight among groups I, II, III, IV, V and VI. Differences in body weights of the test and control groups were statistically significant from 3 days post-challenge (P=0.0006). Those mice that died from infectious disease displayed obvious lesions, including severe necrosis of the liver and spleen, diffuse gastric bleeding and body weight loss. P. multocida was also recovered from the organs of deceased mice.
DISCUSSION
P. multocida is an opportunistic respiratory pathogen of sheep and goats, causing high morbidity and mortality rates [17] . Thus, development of new-generation vaccine systems to prevent infection is important in avoiding the disadvantages of currently used vaccines. The induction of potent cellular immune responses often gives DNA vaccination an immunological advantage over subunit protein vaccination [18] . In this study, we demonstrated the ability of a Only IIV+bDNA protected the mice. Differences between control and treated groups were tested for significance using the log-rank test (P=0.0002).
subcutaneously delivered formalin and iron-inactivated P. multocida vaccine co-formulated with bDNA and alum to induce humoral and cellular immunity, as well as protection from P. multocida challenge, in mice.
Metals play a vital role in the metabolic processes of the microorganism, and some of the heavy metals are required by the organism as micronutrients. However, at high concentrations, heavy metal ions react to form toxic compounds in bacterial cells [19, 20] . In the present study, we showed the effect of differing concentrations of ferric chloride (FeCl 3 ) on P. multocida. We inactivated P. multocida using 10 mM FeCl 3 , which resulted in its total inactivation within 24 h. The inactivating effect of FeCl 3 is achieved by its ability to precipitate proteins in the cell wall and to degrade nucleic acids and lipids through free radical reactions [13, 19] . Degradation of nucleic acid by a high concentration of ferric chloride was demonstrated in a study by Kumar and Singh [12] . Thereby, higher iron contents in IIV could have a beneficial effect on the immune response. The higher antibody levels achieved in IIV-than in FIV-inoculated mice during the course of primary and secondary immune response development might thus be due to adjuvant action of excess iron in the former vaccine [12, 15] .
The main adjuvants currently approved for human use by the US Food and Drug Administration (FDA) are aluminum-based mineral salts, the most commonly used of which is aluminum hydroxide (alum). For decades, alum has been used successfully in vaccine preparations and has a good safety record [7] . Results have determined that animals vaccinated with a commercial alum-precipitated vaccine were not able to develop and sustain sufficient levels of specific antibody for a long duration [21] . Selection of appropriate adjuvants that boost antigen immunogenicity is one of the critical steps in vaccine development. CpG-motifs containing bacterial DNA have been utilized as vaccine adjuvants in studies on animals, because they induce Th1-type cellmediated immunity as evidenced by increased IFN-g through binding to Toll-like receptor 9 (TLR9), which is involved in the recognition of pathogen-associated molecular patterns (PAMP) [22] .
CpG ODN bind Toll-like receptor 9, inducing production of interleukins-1 (IL-1), IL-6, IL-12 and tumour necrosis factor alpha (TNF-a) by dendritic cells and macrophages, as well as the production of IL-6 and gamma interferon (IFN-g) by natural killer (NK) cells [9] . TLR9-stimulated B cells also secrete IgM in a process partially dependent on IL-6 expression [23] . Bacterial DNA behaves as a PAMP, exerting stimulatory effects on human and murine immune cells both in vitro and in vivo [11] . We chose 5 µg homologous P. multocida bDNA in the present study as an adjuvant, and DNA was purified using the phenol/chloroform extraction method. Herath et al. found that immunization with IIV5µg bDNA induced higher antibody levels than IIV-10µg bDNA [13] .
The humoral immune response is an important factor in resistance to P. multocida infection. In this study, the ELISA procedure was used to detect the levels of serum antibody induced by the inactivated vaccines (FIV and IIV). We found that immunized groups produced antibody at different levels, and the highest antibody titres as measured by ELISA were observed on day 28 for the IIV+bDNA vaccine. Indirect ELISA results showed that the humoral immune response in mice vaccinated with IIV+bDNA was superior to that induced by other experimental vaccines. Kumar and Singh also found that mice immunized with DNAadjuvanted vaccines produced higher antibody levels and that homologous bDNA can protect mice from Salmonella typhimurium [12] .
The cellular immunologic response also plays an influential role in the process of anti-infection [18] . An antigen-specific T-cell response can be induced when mice are inoculated s/ c with bDNA-adjuvanted vaccine. Lymphocyte proliferation assay is a method commonly used to detect cellular immune function [18] . To determine whether the mice had developed cell-mediated immunity to P. multocida, spleen cell culture supernatants of three vaccinated and two control groups were assayed for the presence of IL-6 and IL-12. To date there has been no report on splenocyte cultures stimulated with bDNA and P. multocida antigen for the detection of IL-12 levels in mice. In the present study, we showed that the addition of bDNA to the FIV and IIV (FIV+bDNA, IIV +bDNA) vaccines resulted in significant increases in production of both IL-6 and IL-12, whereas there was no effect with FIV+Alum and IIV+Alum. bDNA enhanced the immune response and the immune protection induced by the CpG motif [9, 10] .
Okay et al. [22] determined serum IFN-g levels in mice vaccinated i/p with oil-based rPlpE, rOmpH and PlpEC-OmpH formulated with oil-based CpG ODN adjuvants, by ELISA. Oil-based CpG ODN-adjuvanted formulations significantly increased serum IFN-g titres after first and second vaccinations, but the increments were not statistically significant with oil-based adjuvant alone. They showed that rPlpE, rOmpH and PlpEC-OmpH fusion proteins provided 80-100, 40 and 60-100% homologous protection, respectively, depending on the adjuvant used in the formulation [22] . In the present study, protective immunity developed in mice after either FIV or IIV vaccination with P. multocida antigen, and one of the vaccine preparations we tested (IIV +bDNA) resulted in complete protection against P. multocida infection. These results confirmed the superior immunity promotion potential of bDNA. Similarly, IIV+bDNA has been proved to enhance the immunity of mice to S. typhimurium vaccine [12] , and chickens to P. multocida A:1 vaccine [13] .
In the present study, we demonstrated that FeCl 3 used in combination with bDNA induced protection against a lethal challenge in standard Balb/c mice for pasteurellosis, and also induced long-term protection against infection. Furthermore, this work suggests that the use of bDNA as an adjuvant could improve the cost-effectiveness of inactivated veterinary vaccines for use in developing countries. The adjuvant effect of homologous bacterial DNA in both IIV and FIV was clearly perceptible in terms of cytokine levels, which were statistically significantly higher than those in the groups vaccinated with no DNA. Our future studies will focus on the safety and potency evaluation of different bacterial genomes as adjuvant.
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